Centessa Pharmaceuticals plc
CNTA
$16.52
-$0.48-2.82%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 118.88% | 118.88% | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 118.88% | 118.88% | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 118.88% | 118.88% | -- | -- | -- |
| SG&A Expenses | 3.10% | -2.76% | -5.43% | -10.45% | -11.74% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 36.41% | 27.45% | 12.87% | -5.18% | -12.98% |
| Operating Income | -32.78% | -23.50% | -17.38% | 9.03% | 16.66% |
| Income Before Tax | -43.52% | -34.47% | -32.23% | 14.09% | 19.81% |
| Income Tax Expenses | 872.78% | 114.89% | 111.35% | 110.94% | 97.95% |
| Earnings from Continuing Operations | -46.41% | -61.72% | -56.04% | -2.44% | 8.86% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -46.41% | -61.72% | -56.04% | -2.44% | 8.86% |
| EBIT | -32.78% | -23.50% | -17.38% | 9.03% | 16.66% |
| EBITDA | -32.95% | -23.51% | -17.22% | 9.28% | 16.93% |
| EPS Basic | -14.46% | -27.31% | -26.63% | 7.78% | 14.59% |
| Normalized Basic EPS | 2.66% | 7.32% | 4.72% | 21.90% | 23.46% |
| EPS Diluted | -14.46% | -27.31% | -26.63% | 7.78% | 14.59% |
| Normalized Diluted EPS | 2.66% | 7.32% | 4.72% | 21.90% | 23.46% |
| Average Basic Shares Outstanding | 27.50% | 25.98% | 18.98% | 11.07% | 6.57% |
| Average Diluted Shares Outstanding | 27.50% | 25.98% | 18.98% | 11.07% | 6.57% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |